



European Biotechnology

Summer 2025

Official Media Partner of



Preview

Summer 2025

Lab automation: New modalities

SPECIAL

Publication date:
26 June, 2025

New Modalities

Hot topics in automated screening & expression of new modalities

Whether antibody conjugates (ADCs or radiopharmaceuticals), T-cell, NK-cell or MAIT engagers, bispecific checkpoint inhibitors, molecular condensate inhibitors or Protac: Time-saving and error-averse automated screening and expression procedures, virtual docking, ML-based simulation and validation cycles play a key role in the drug development process. European Biotechnology Magazine, in cooperation with its official partner, the Society of Laboratory Automation & Screening, take a closer look at the relevant technologies, developers, AI tools and service providers in a special feature. Don't miss this unique opportunity to present your service, pipeline or platform in an excellent editorial environment.

Present your expertise

CROs offering phage/ribosome display, protein expression, ADMET and protein stability optimisation, as well as formulation, anti aggregation and drug delivery services along with (coding/non-coding) RNA-drug and vaccine developers are invited to present their offerings right to our highly specialised professional readership, including 20,000+ SLAS members. European Biotechnology Magazine goes out to decision makers throughout the entire European life sciences sector and lab automation executives in the US and Europe. Take advantage of the journal's highly relevant readership and grab this opportunity to target your audience!

Topics to be covered

AI/ML-guided antibody selection, enhancing target selectivity, predicting ADEs such as CRS, ADCs, TCEs, bispecific antibodies, structural genomics/AI, CRISPR/Base editing, display technologies, affinity modulation of antibodies, probody engineering, TME-selective activation of modalities, multispecific modalities, tactics to improve the therapeutic index of new modalities, automated GMP-compliant manufacturing, allogenic gene/cell therapies.

Editorial Deadline
11-6-2025

Editorial Contact:
Thomas Gabrielczyk
Tel.: +49-30-264921-50
Fax: +49-30-264921-11
t.gabrielczyk@biocom.de

Booking Deadline
13-6-2025

Marketing Contact:
Oliver Schnell
Tel.: +49-30-264921-45
Fax: +49-30-264921-11
o.schnell@biocom.de

Publication Date
26-6-2025

Marketing Contact:
Andreas Macht
Tel.: +49-30-264921-54
Fax: +49-30-264921-11
a.macht@biocom.de

Special: Automation - New Modalities

Meet your audience!

European Biotechnology

is published in co-operation with
the following organisations:



Europe: european-biotechnology.net



Young European Biotech Network

Europe: yebn.eu



Austria: lifescienceaustria.at



Austria: biotechaustria.org



Come Transform Research

United States: slas.org



Europe: medicinesforeurope.com



Ireland: ibec.ie/ibia



Denmark: danskbiotek.dk



The Netherlands: hollandbio.nl



Germany: gasb.de



Portugal: www.p-bio.org



UK: biopartner.co.uk



France: france-biotech.org



Italy: assobiotec.federchimica.it



Sweden: swedenbio.com



Hungary: hungarianbiotech.org



Europe: cebr.net



Spain: asebio.com



Norway: bioteknologiradet.no



Finland: suomenbioteollisuus.fi



Belgium: bio.be



Switzerland: swissbiotech.org

EUROPEAN BIOTECHNOLOGY covers the biotechnology sector of the current 27 EU member states, Norway, Switzerland, and UK. If you would like to subscribe, please refer to european-biotechnology.com